|
Aug 5
|
Clene to Present at the Canaccord 45th Annual Growth Conference
|
|
Aug 4
|
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
|
|
Jul 16
|
Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream
|
|
Jun 30
|
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
|
|
Jun 25
|
Q2 Virtual Investor Summit: Presentations Available Now
|
|
Jun 24
|
When Will Clene Inc. (NASDAQ:CLNN) Breakeven?
|
|
Jun 9
|
Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
|
|
Feb 25
|
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction
|
|
Dec 30
|
IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)
|
|
Oct 11
|
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements
|
|
Oct 9
|
IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
|
|
Oct 9
|
Clene to Present at Upcoming October Conferences
|
|
Oct 3
|
IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M
|
|
Oct 2
|
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements
|
|
Oct 1
|
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility
|
|
Sep 30
|
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
|
|
Sep 26
|
IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership
|
|
Aug 29
|
IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast
|
|
Aug 13
|
IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions
|
|
Aug 12
|
IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
|